Skip to main content
logo
XORTX Therapeutics Inc. (XRTX)
0.3791
+0.0341 (9.88%)
Inactive · Last trade price on Mar 27, 2026

XORTX Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-2.77-2.66-3.31-2.16-7.72-1.58
Depreciation & Amortization
0.080.110.120.140.060.01
Stock-Based Compensation
0.020.030.120.120.490.46
Other Adjustments
-0.35-0.59-0.72-3.66-2.47-2.61
Change in Receivables
-0.05-0.060.040.02-0.04-0.03
Changes in Accounts Payable
0.270.24-0.13-1.190.89-0.26
Changes in Other Operating Activities
0.130.160.210.140.62-0.79
Operating Cash Flow
-2.63-2.77-3.68-6.58-8.17-4.8
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
----0-0.02-
Purchases of Intangible Assets
-0.06-0.06-0.04-0.04-0.03-0.03
Other Investing Activities
--0.24----
Investing Cash Flow
-0.3-0.29-0.04-0.05-0.05-0.03

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
2.142.263.520520.07
Net Common Stock Issued (Repurchased)
2.142.263.520520.07
Other Financing Activities
-0.44-0.83-0.74-0.36-1.09-0.7
Financing Cash Flow
1.261.432.78-0.363.9119.37

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.030.03-0.040-0.140.2
Net Cash Flow
-1.64-1.61-0.97-6.99-4.4414.74

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-2.63-2.77-3.68-6.59-8.19-4.8
Free Cash Flow Growth
------
Free Cash Flow Per Share
-2.37-2.92-6.39-16.62-27.66-21.94
Levered Free Cash Flow
-0.32-2.15-3.12-3.07-6.17-2.62
Unlevered Free Cash Flow
-2.63-2.75-3.93-6.96-8.74-3.95
SEC Filings: 10-K · 10-Q